600 patients66,869 observations120 daysLIVE

Patient P-01543

Synthetic patientNBL-101 · Day 115 · 75+ · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
75%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 49 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 58 GI-04 recommendedGI Support Protocol GI-04
  4. Day 59 Patient acceptedStarted GI-04 in the companion
  5. Day 67 GI symptom burden −32% vs expectedGI Support Protocol GI-04
  6. Day 70 ME-01 recommendedMonitoring Escalation ME-01
  7. Day 71 Patient acceptedStarted ME-01 in the companion
  8. Day 73 Tolerance state changedUnstable → Improving
  9. Day 74 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days
  • GI instability+11
  • Toxicity-6
  • Inflammatory activity+4
  • Treatment adherence-4
  • Nutritional resilience-2

What helped?

  • GI Support Protocol GI-04Day 58
    Result: symptom burden −32%
  • Monitoring Escalation ME-01Day 70
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
63%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
46.9/100
worsening · +3.8 vs previous 14 d
Toxicity
Blood
34.5/100
improving · -5.5 vs previous 14 d
Sleep quality
Wearable
46.7/100
stable · -1.1 vs previous 14 d
Energy level
Daily log
3.8/10
stable · -0.0 vs previous 14 d
Stress level
Daily log
5.2/10
stable · +0.1 vs previous 14 d
Steps
Wearable
2,037
worsening · -370 vs previous 14 d
Adherence
Companion
43.3 %
worsening · -3.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 42 from the failing basin, 45 from restoration.

Would help
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 78%
  • CR-01 Clinician Review
    100% improved among 8 similar · onset 5 d · confidence 78%
Would not help
  • Keep spicy low
    GI +6.3 next day on high-intake days · n 17
  • Keep histamine low
    GI +6 next day on high-intake days · n 22
  • Keep fat low
    GI +5.9 next day on high-intake days · n 22
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Spicy / capsaicin
    +6.3detractor · 95%
  • Histamine load
    +6detractor · 95%
  • Dietary fat load
    +5.9detractor · 95%
  • Insoluble fibre
    +3.5detractor · 83%
  • Simple carbohydrates
    +2.2no signal · 41%
  • Alcohol
    0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 44/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Drug metabolism and exposure 75
    • DNACYP2D6 poor metabolizer → higher exposure
    • DNADPYD *2A → slower clearance
  • Inflammatory signalling 65
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 47
    • WearableHRV 36 ms, trending down
  • Mucosal barrier integrity 50
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • Daily logGI symptom score 47 and rising
  • Autonomic recovery 45
    • WearableResting HR 79 bpm
    • Wearable2,037 steps/day
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • DPYD *2A heterozygous
    Slower drug clearance
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 3.1 · butyrate capacity 44/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
37 ms
Sleep
7.4 h
Steps
3,138
Resting HR
81 bpm
Daily log: GI score 47, nutritional resilience 49, adherence 43.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0132743%S01GI-04improved56
P-0168842%S01GI-04improved40
P-0181331%S01NP-02no change40
P-0131030%S0157
P-0182326%S0157
P-0187726%S01CR-01improved67
P-0160425%S0171
P-0182125%S0158
P-0163545%S02GI-04improved49
P-0145234%S02GI-04improved46
P-0145931%S0251
P-0149925%S0265